glp-1observational-studiescardiovascular-research
Claims-data comparison of tirzepatide vs semaglutide: what the head-to-head analysis means for researchers
A large claims-based comparative study compared cardiovascular outcomes in nearly one million adults on tirzepatide, semaglutide, or other diabetes agents; both GLP-1–pathway agents showed measurable reductions in major events, with differe
April 29, 2026
